ONO-4059 analog

• CAT Number: I001351
• CAS Number: 1351635-67-0
• Molecular Formula: C₂₅H₂₄N₆O₃
• Molecular Weight: 456.51
• Purity: ≥95%
• Synonyms: (S)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one
• Target: BTK
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: sub-nM range
• IUPAC Name: 6-amino-7-(4-phenoxyphenyl)-9-[(3S)-1-prop-2-enoylpiperidin-3-yl]purin-8-one
• InChI: InChI=1S/C25H24N6O3/c1-2-21(32)29-14-6-7-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-10-12-20(13-11-17)34-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m0/s1
• InChIKey: KSUDUUBCXJUFRL-SFHVURJKSA-N
• SMILES: C=CC(=O)N1CCC[C@@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N

ONO-4059 analog（Cat No.:I001351）is a selective inhibitor of Bruton’s tyrosine kinase (BTK), similar to ONO-4059, which plays a key role in B-cell receptor signaling. By targeting BTK, this analog inhibits the activation and proliferation of B-cells, making it a valuable tool for studying B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma. It also holds potential in research related to autoimmune diseases like rheumatoid arthritis, where B-cell activity is dysregulated. This analog is crucial for advancing the development of targeted therapies in oncology and immunology.

Reference

[1]. Simon Rule,A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. November 15, 2013; Blood: 122 (21)
[2]. Toshio Yoshizawa, et al. Development of a Bruton/’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). Washington, DC November 9-14, 2012.
[3]. Yamamoto, et al. Preparation of purinone derivatives as selective Btk inhibitors. From PCT Int. Appl. (2011), WO 2011152351 A1 20111208.